Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1997;96:1305-1312

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Kloner, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Kloner, R. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM CHLORIDE
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Medline Plus Health Information
*Heart Attack

(Circulation. 1997;96:1305-1312.)
© 1997 American Heart Association, Inc.


Articles

Is Calcium a Mediator of Infarct Size Reduction With Preconditioning in Canine Myocardium?

Karin Przyklenk, PhD; Katsuya Hata, MD, PhD; ; Robert A. Kloner, MD, PhD

From the Heart Institute, Hospital of the Good Samaritan, and Department of Medicine, Section of Cardiology, University of Southern California, Los Angeles.

Correspondence to Karin Przyklenk, PhD, Heart Institute/Research, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background The cellular mechanisms by which brief episodes of ischemia protect or "precondition" the heart and limit infarct size caused by a later period of sustained coronary artery occlusion remain unresolved. We propose that calcium may be an important mediator in eliciting this cardioprotection.

Methods and Results To test this hypothesis, anesthetized dogs received a 15-minute intracoronary infusion of 20 mmol/L CaCl2 or saline before undergoing 1 hour of coronary occlusion and 4 hours of reperfusion (protocol 1). Collateral blood flow during occlusion was measured with radiolabeled microspheres, area at risk of infarction (AR) was delineated by injection of blue dye, and area of necrosis (AN) was determined by tetrazolium staining. AN/AR was reduced from 20±5% in the saline-treated controls to 9±3% in CaCl2-treated dogs (P<.05). Additional animals underwent 10 minutes of preconditioning ischemia or a comparable waiting period before the 1-hour test occlusion (protocol 2). Administration of 5-(N,N-dimethyl)-amiloride (an inhibitor of calcium influx via Na+-H+ and Na+-Ca2+ exchange) before the preconditioning stimulus attenuated the protective effect of ischemic preconditioning: AN/AR was 12±1%, larger than the value of 4±1% observed in preconditioned dogs that received saline (P<.05) and comparable to the values of 12±3% and 14±3% seen in saline- and dimethylamiloride-treated controls.

Conclusions Brief intracoronary infusion of CaCl2 mimicked, whereas treatment with dimethylamiloride blocked, infarct size reduction with preconditioning, thereby implicating calcium as a mediator of preconditioning in this canine model.


Key Words: calcium • ischemia • myocardial infarction • signal transduction


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
There is no doubt that one or more episodes of brief ischemia protect or "precondition" the heart and reduce infarct size caused by a subsequent sustained period of coronary artery occlusion. However, the cellular mechanism(s) responsible for this paradoxical protection remain controversial. For example, activation of the adenosine-regulating enzyme ectosolic 5' nucleotidase and translocation of PKC to myocyte membranes at the onset of sustained occlusion1 2 3 4 have both been proposed to play important roles in eliciting cardioprotection, yet data from our laboratory and others5 6 7 8 have failed to support these hypotheses.

Regulation of ionic homeostasis, particularly calcium, is a crucial determinant of myocyte viability. Considerable evidence indicates that brief, nonlethal episodes of myocardial ischemia are associated with a brief, transient, and reversible increase in cytosolic calcium concentrations, whereas a massive increase in total calcium content is a hallmark of myocytes irreversibly injured by prolonged ischemia/reperfusion.9 10 11 12 13 14 15 This focal role of calcium led us to postulate that a brief, transient, and modest increase in intracellular calcium concentration during the preconditioning stimulus may be an important component of the second-messenger pathway ultimately responsible for the reduction of infarct size seen with ischemic preconditioning. If so, then brief intracoronary infusion of calcium in lieu of brief ischemia should mimic the protective effects of preconditioning. Moreover, because calcium influx during ischemia/reperfusion occurs at least in part as a secondary consequence of intracellular acidosis and resultant activation of Na+-H+ and Na+-Ca2+ exchange,11 12 13 14 15 we further proposed that the selective Na+-H+ exchange inhibitor DMA,16 administered during the preconditioning stimulus, should attenuate the reduction of infarct size seen with preconditioning. Using the anesthetized canine model, we sought to determine whether calcium may serve as a mediator of infarct size reduction with preconditioning by evaluating each of these two corollaries.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
This study was approved by the Institutional Animal Care and Use Committee of the Hospital of the Good Samaritan (an American Association for Accreditation of Laboratory Animal Care–certified institution) and conforms to the Position of the American Heart Association on Research Animal Use (Circulation. 1985;71:849).

Surgical Preparation
Seventy-four mongrel dogs weighing between 14 and 32 kg were anesthetized with sodium pentobarbital (30 mg/kg), intubated, and ventilated with room air. After cannulation of the left jugular vein (for administration of fluids and supplemental anesthesia) and the left carotid artery (for measurement of heart rate and arterial pressure), the heart was exposed through a left lateral thoracotomy and suspended in a pericardial cradle. A fluid-filled catheter was positioned in the left atrium for later injection of radiolabeled microspheres (141Ce, 103Ru, or 95Nb) for measurement of RMBF, and a microtipped pressure transducer was positioned in the LV cavity via the left atrial appendage for measurement of LV pressure and its first derivative, LV dP/dt. A segment of the LAD was isolated, usually distal to its first major diagonal branch, for later placement of occlusive vascular clamps, and a second segment was isolated for placement of a Doppler flow probe for measurement of mean CBF.

Protocol 1: Intracoronary Calcium Infusion
In the 28 dogs enrolled into the first limb of the study, a proximal branch of the LAD was cannulated with a 24-gauge catheter, and the tip was advanced into the lumen of the main LAD. Each dog was randomized to receive a 15-minute IC infusion of either CaCl2 (concentration of 20 mmol/L infused at a rate of 0.5 mL/min, ie, 1.47 mg/min) or saline (0.5 mL/min) into the soon-to-be-ischemic LAD bed, followed by a 10-minute saline "washout" at 0.5 mL/min (Fig 1Down). This "dose" was selected, on the basis of work by Ito et al,17 such that a small but consistent increase in LV dP/dt (suggestive of a modest increase in intracellular calcium concentration) was obtained during CaCl2 infusion compared with baseline but with no significant differences between the saline- and calcium-treated groups. All dogs then received a prophylactic dose of lidocaine ({approx}1.5 mg/kg IV bolus) and underwent 1 hour of sustained LAD occlusion followed by 4 hours of reperfusion. Hemodynamics and CBF were monitored before and during saline or calcium infusion, before and throughout sustained LAD occlusion, and after sustained reflow. In addition, the severity of ischemia was assessed in all dogs by measurement of RMBF at 30 minutes into the prolonged LAD occlusion.



View larger version (45K):
[in this window]
[in a new window]
 
Figure 1. Experimental protocols. i.c. indicates intracoronary; LAD CO, LAD occlusion.

At the end of the protocol, the LAD was ligated at the site of previous occlusion, and Unisperse blue pigment (0.25 to 0.5 mL/kg) was injected into the coronary vasculature via the left atrial catheter to delineate the in vivo extent of the occluded LAD bed, or AR. Under deep anesthesia, cardiac arrest was produced by intracardiac injection of KCl. The hearts were rapidly excised, cut into five to seven transverse slices, and photographed for later measurement of AR. To distinguish necrotic from viable myocardium, the standard method of incubation for 10 minutes in a 1% solution of triphenyltetrazolium chloride at 37°C was used,5 8 and the heart slices were rephotographed for later calculation of the AN and stored in formalin.

Protocol 2: Effect of DMA on Ischemic Preconditioning
Of the 46 animals entered into the second limb of the study, 20 were assigned to undergo one 10-minute episode of preconditioning ischemia and 30 minutes of reperfusion before the 1-hour sustained test occlusion (Fig 1Up). Immediately before preconditioning, either DMA (400 µmol/L, n=12) or saline (n=8) was administered directly into the soon-to-be-ischemic LAD territory via {approx}30 intramyocardial injections (0.15 mL each) into the subendocardium at a depth of 8 to 10 mm, an approach successfully used by our laboratory and others to facilitate local drug delivery in the absence of deleterious and confounding hemodynamic consequences.5 7 18 The remaining 26 dogs served as controls and received {approx}30 intramyocardial injections of DMA (n=15) or saline (n=11) followed by an equivalent 40-minute waiting period before the 1-hour sustained occlusion. Hemodynamics and CBF were monitored at frequent intervals throughout the protocol, RMBF was measured at 30 minutes into the sustained LAD occlusion, and infarct size was delineated as described in protocol 1.

Exclusion Criteria
Dogs from either protocol were excluded from analysis according to the following standard prospective criteria: (1) high collateral blood flow, defined as values of RMBF to the "ischemic" subendocardium >0.20 mL·min-1·g tissue-1; (2) a small AR, defined as AR <10% of the LV; or (3) intractable VF, unresponsive to cardioversion with low-energy (20- to 30-J) DC pulses applied directly to the heart.

Analysis
AR and infarct size. After fixation, right ventricular tissue was trimmed from each heart slice, and the remaining LV tissue was weighed. Photographic images of the heart slices were projected and traced at magnifications of {approx}x2 to x4. The extent of the AR and AN in each heart slice was quantified by computerized planimetry, corrected for the weight of the tissue slice, and summed for each heart.

Regional myocardial blood flow. After LV weights had been obtained, tissue blocks were cut from the center of the previously ischemic LAD bed and remote, normally perfused circumflex bed and divided into subendocardial, midmyocardial, and subepicardial segments. RMBF was then quantified by the standard method described previously.5 8

Hemodynamics and CBF. Heart rate and arterial pressures were measured and averaged over five continuous cardiac cycles in sinus rhythm for each sample period. Mean CBF was also recorded during these same five cardiac cycles and expressed as a percentage of CBF measured at baseline.

Statistics
Because protocols 1 and 2 were conducted consecutively and not concurrently, statistical analyses were performed separately for each limb of the study. In protocol 1, RMBF, risk region, and infarct size in calcium- and saline-treated animals were compared by unpaired t tests, and the incidence of VF was compared by Fisher's exact test. ANCOVA was used to determine whether the relationship between infarct size and collateral blood flow differed between the two groups. Hemodynamic parameters were compared at baseline, at 15 minutes into CaCl2/saline infusion, before sustained occlusion, at 30 minutes and 1 hour into sustained occlusion, and at 15 minutes, 1 hour, and 4 hours after reperfusion by two-factor ANOVA (for treatment and time) with repeated measures across the second factor, and if significant F ratios were obtained, subsequent pairwise comparisons were made by Tukey's test. Statistical comparisons for protocol 2 were done in a similar manner, except discrete variables (RMBF, risk region, infarct size) were compared by ANOVA followed by Tukey's test. All data are expressed as mean±SEM, and values of P<.05 were considered to be statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Protocol 1
Mortality and exclusions. Of the 28 dogs enrolled in protocol 1, 14 were assigned to each of the IC CaCl2 and saline infusion groups (Table 1Down). Seven saline-treated controls and 4 calcium-treated dogs developed VF (P=NS between groups), with successful cardioversion achieved in 2 animals (1 saline and 1 calcium). In addition, 3 dogs that received IC CaCl2 were excluded on the basis of high collateral blood flow. Data are therefore reported for the 8 saline- and 8 calcium-treated dogs that successfully completed the protocol.


View this table:
[in this window]
[in a new window]
 
Table 1. Mortality and Exclusions

Hemodynamics. Baseline values of heart rate, arterial pressure, and dP/dt were similar in both groups (Table 2Down). Comparison of hemodynamic parameters measured at the end of the 15-minute IC infusion with their respective baseline values revealed, as expected, a small but consistent increase in LV dP/dt in the CaCl2-treated group (1618±159 versus 1416±139 mm Hg/s, P<.01). There was, however, no significant difference with saline infusion (1488 versus 1454 mm Hg/s) and no significant difference between groups. When data obtained throughout infusion, occlusion, and reperfusion were included in the statistical analysis, this modest increase in LV dP/dt with CaCl2 infusion did not achieve significance.


View this table:
[in this window]
[in a new window]
 
Table 2. Hemodynamics

Coronary blood flow remained stable at {approx}100% of baseline throughout IC infusion of calcium or saline. All dogs were hyperemic upon reperfusion, with CBF remaining comparable between the groups throughout the 4 hours of reflow.

Regional myocardial blood flow. Collateral blood flow during sustained LAD occlusion was similar in saline- and calcium-treated animals: ie, subendocardial RMBF was 0.06±0.02 and 0.05±0.02 mL·min-1·g-1, respectively (Table 3Down). In addition, RMBF measured in the normally perfused circumflex bed during LAD occlusion did not differ between groups.


View this table:
[in this window]
[in a new window]
 
Table 3. RMBF During Sustained LAD Occlusion

Risk region and infarct size. AR tended to be larger in the calcium-treated group than in the saline controls (23±2% versus 19±1% of the total LV weight, P=.07; Fig 2ADown). Nonetheless, infarct size in dogs treated with IC CaCl2 averaged only 9±3% of the AR (or 2.1% of the total LV), significantly smaller than the value of 20±5% (or 3.9% of the total LV) observed in animals that received IC saline (P<.05; Fig 2ADown). This reduction in infarct size with IC CaCl2 was confirmed by ANCOVA: when collateral blood flow was incorporated as a covariate, the relationship between AN/AR and subendocardial RMBF was shifted downward for calcium-treated animals versus saline controls (P<.03; Fig 2BDown).



View larger version (16K):
[in this window]
[in a new window]
 
Figure 2. A, Mean values of AR (as % of total LV weight) and AN (as % of AR) for protocol 1, comparing saline- and CaCl2-treated groups. *P<.05 vs saline. B, AN/AR plotted as a function of RMBF to the ischemic subendocardium (Endo) during coronary occlusion for dogs in protocol 1. There was a significant downward shift in regression relationship between infarct size and collateral flow in dogs that received CaCl2 vs saline controls.

Protocol 2
Mortality and exclusions. Of the 46 dogs entered into the second limb of the study, 8 received intramyocardial saline and 12 received intramyocardial DMA before 10 minutes of preconditioning ischemia, and 26 controls (11 treated with saline and 15 with DMA) received intramyocardial injections before the 40-minute waiting period (Table 1Up). Of the 2 saline-preconditioned, 6 DMA-preconditioned, 8 saline control, and 6 DMA control dogs that developed VF (P=NS), both saline-preconditioned, 4 DMA-preconditioned, 2 saline control, and 2 DMA control dogs were successfully resuscitated. Three DMA control dogs were excluded because of high collateral blood flow, and 1 DMA-preconditioned animal was excluded because of technical difficulties. Thus, a total of 5 saline control, 8 DMA control, 8 saline-preconditioned, and 9 DMA-preconditioned animals completed the protocol.

Hemodynamics. Animals assigned to the DMA-preconditioned group tended to have higher values of heart rate, mean arterial pressure, and LV dP/dt at baseline (ie, before randomization), and for both heart rate and arterial pressures, this trend persisted throughout much of the protocol (Table 2Up). However, only two treatment effects attained statistical significance: heart rate was transiently increased by 16 to 19 bpm with intramyocardial saline injections (P<.05 for the saline-preconditioned group), and peak positive dP/dt in the DMA control cohort increased from 1281 mm Hg/s at baseline to 1500 mm Hg/s immediately before sustained occlusion (P<.05).

Coronary blood flow increased to {approx}130% of baseline values in all groups in response to intramyocardial injection of either DMA or saline. CBF returned to 96% to 101% of baseline in all groups before the onset of sustained occlusion, and all dogs exhibited hyperemia upon reperfusion.

Regional myocardial blood flow. Collateral blood flow during sustained occlusion was similar in all groups, ie, mean subendocardial RMBF in the LAD bed ranged from 0.02 to 0.05 mL·min-1·g tissue-1 (Table 3Up). RMBF in the normally perfused circumflex bed was also comparable among the four cohorts.

Risk region and infarct size. AR in the four groups averaged 18% to 21% of the total LV weight (P=NS; Fig 3ADown).



View larger version (34K):
[in this window]
[in a new window]
 
Figure 3. A, Mean values of AR (as % of total LV weight) and AN (as % of AR) for protocol 2, comparing control and preconditioned (PC) animals treated with saline and DMA. *P<.05 vs saline controls, DMA controls, and DMA PC. B, AN/AR plotted as a function of RMBF to ischemic subendocardium (Endo RMBF) during coronary occlusion for dogs in protocol 2. There was a significant downward shift in regression relationship between infarct size and collateral flow in saline-PC dogs vs saline and DMA controls (left) and an upward shift for animals in DMA-PC cohort vs saline-PC group (right).

Mean infarct size in the saline and DMA control groups was 12±3% and 14±3% of the AR, respectively (P=NS). As expected, AN/AR was significantly smaller in the saline-preconditioned group, averaging only 4±1% (P<.01; Fig 3AUp), and ANCOVA revealed a significant downward shift in the regression relationship between infarct size and subendocardial collateral blood flow for saline-preconditioned dogs compared with controls (P<.05 versus saline controls; P<.02 versus DMA controls; P<.01 versus all controls; Fig 3BUp). In contrast, infarct size in the DMA-preconditioned cohort was 12±1%, significantly greater than the value of 4% obtained in saline-preconditioned animals and comparable to the infarct sizes of 12% and 14% seen in the saline and DMA controls (Fig 3AUp). Moreover, the regression relationship for the DMA-preconditioned group was shifted upward compared with the saline-preconditioned group (P<.01; Fig 3BUp) and did not differ from that of the controls (P=.9).

The apparently chance trend of higher heart rates and arterial pressures in the DMA-preconditioned group raises the concern that the larger infarct sizes in these animals versus saline-preconditioned dogs were simply due to higher oxygen demand during occlusion. Importantly, however, when AN/AR for the DMA- and saline-preconditioned groups was plotted as a function of hemodynamic parameters measured midway during the sustained occlusion, we observed no correlation between infarct size and heart rate, mean arterial pressure, or their product (all P>=.44; Fig 4Down). These results indicate that the larger infarct sizes obtained in DMA-preconditioned dogs were due to an attenuation of the preconditioning effect by DMA.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 4. AN (as % of AR) plotted as a function of product of heart rate (HR) and mean arterial pressure (MAP) measured at 30 minutes into LAD occlusion for preconditioned (PC) dogs that received DMA and saline. No correlation was observed between these two parameters.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
In the present study, we demonstrate that a brief 15-minute IC infusion of CaCl2 before 1 hour of sustained coronary occlusion significantly reduced infarct size compared with controls that received a comparable infusion of saline. In addition, intramyocardial injection of DMA essentially reversed the protective effects of a 10-minute episode of brief preconditioning ischemia. These results support the concept that calcium may serve as a cellular mediator of infarct size reduction with preconditioning in this canine model.

Brief Transient Calcium Infusion Protects the Heart Against Subsequent Sustained Ischemia
Our results showing infarct size reduction with brief infusion of CaCl2 are in agreement with preliminary reports in the dog model19 20 and recent evidence obtained in isolated buffer-perfused rat hearts21 : IC infusion of CaCl219 20 and CaCl2 added to the perfusate21 limited infarct size caused by subsequent sustained occlusion and enhanced the acute recovery of contractile function after relief of ischemia in the two models, respectively. Because 20 mmol/L CaCl2 produced only a modest ({approx}200 mm Hg/s) increase in LV dP/dt, our results indicate that the cardioprotective effects of brief preischemic administration of calcium are not simply due to relative demand-induced ischemia during infusion.

DMA Attenuates the Cardioprotective Effects of Ischemic Preconditioning
The obvious question arising from protocol 1 is, Does the cardioprotection seen with brief exogenous calcium infusion and ischemic preconditioning share a common pathway? Considerable evidence indicates that transient, nonlethal episodes of ischemia are associated with brief, transient, and reversible increases in cytosolic calcium concentrations.9 10 12 13 14 Calcium influx during brief ischemia is, at least in part, a secondary consequence of intracellular acidosis: the increase in intracellular concentrations of H+ stimulates Na+-H+ exchange, resulting in the extrusion of H+, influx of Na+, and subsequent increase in intracellular calcium via Na+-Ca2+ exchange.11 12 13 15 The importance of this pathway may diminish during prolonged ischemia, because extrusion of H+ and resultant extracellular acidosis serve to inhibit Na+-H+ exchange. However, reperfusion and the resultant washout of extracellular H+ rapidly reactivate Na+-H+ exchange, thereby restoring normal pH at the price of Na+ and subsequent Ca2+ influx.11 12 13 15

To evaluate the potential role of calcium influx via Na+-H+ exchange during the preconditioning stimulus in reduction of infarct size, we administered the selective Na+-H+ exchange inhibitor DMA16 22 by direct intramyocardial injection immediately before 10 minutes of preconditioning ischemia and 30 minutes of intervening reperfusion. Two aspects of our protocol design warrant comment. First, our decision to deliver DMA by intramyocardial injections was based on preliminary experiments in which continuous IC infusion of DMA appeared to precipitate VF (perhaps because of inhibited extrusion of H+ and exacerbated acidosis during brief ischemia/reperfusion), similar to previous observations with high-dose intracoronary infusion of amiloride in anesthetized dogs.23 Our laboratory and others have found intramyocardial injections or microinfusions to be an effective method to administer inotropic and vasoactive compounds such as phorbol myristate acetate, adenosine, and PKC inhibitors5 7 18 directly to the ischemic/reperfused myocardium in the absence of confounding systemic hemodynamic effects. It is important to note, however, that intramyocardial injections per se can initiate cardioprotection: we have found that direct intramyocardial injections of saline alone, made immediately before sustained coronary artery occlusion, significantly limited infarct size in both the rat and dog models because of local stretch and/or focal ischemia at the injection sites.18 Indeed, despite the difference in time course between the two studies (ie, injections made immediately before versus 40 minutes before sustained coronary occlusion), a persistent protective effect of the injections was also observed in the present protocol: mean infarct size in the saline and DMA controls was 12% to 14%, identical to the value of 12% obtained previously in the cohort of dogs in which subendocardial blood flow was <0.20 mL·min-1·g-1 during occlusion18 and smaller than the control values of {approx}20% typically observed in our laboratory (and obtained in protocol 1) with 1 hour of LAD occlusion in this model.5 8

A second issue is our choice of 10 minutes of brief preconditioning ischemia followed by 30 minutes of intervening reperfusion. Our objective was to select a preconditioning regimen that, together with our choice of intramyocardial delivery of DMA, would provide a high probability of large interstitial concentrations of DMA being present throughout preconditioning ischemia and upon reperfusion. However, because considerable evidence indicates that amiloride and its analogues are highly cardioprotective if administered during a sustained period of regional or global myocardial ischemia,22 23 24 25 26 we used a prolonged 30-minute period of intervening reflow to facilitate diffusion and dissipation of DMA before the onset of the sustained test occlusion. As expected,27 10 minutes of ischemia plus 30 minutes of reflow was an effective preconditioning stimulus: this was confirmed in initial pilot experiments (ie, infarct size and subendocardial collateral blood flow averaged 5% and 0.02 mL·min-1·g tissue-1 in 3 dogs preconditioned with 10 minutes of ischemia that did not receive saline injections) and supported by the infarct size of 4±1% observed in our saline-preconditioned cohort.

Intramyocardial injections of DMA blocked the protective effects of preconditioning in our model: AN/AR in the DMA-preconditioned group was 12%, significantly larger than the value of 4% obtained in saline-preconditioned dogs and comparable to the infarct sizes of 12% to 14% in the saline and DMA control groups. The fact that infarct size was similar in both control cohorts may be interpreted to suggest that addition of DMA to the injection fluid failed to attenuate the protective effect of the injections per se, thereby implying that the mechanisms responsible for protection by ischemic preconditioning differ from those of local injections. An alternative explanation, however, is that despite the 40-minute interval between injection and the onset of coronary occlusion, residual amounts of DMA were present in the occluded LAD bed at the onset of sustained occlusion and exerted a modest protective effect (approximately equal in magnitude to that achieved by intramyocardial injections) during the prolonged ischemic insult. Although resolution of this latter issue is beyond the scope of this study, the results of protocol 2 nonetheless indicate that DMA abrogated the protection conferred by brief antecedent ischemia/reperfusion.

Comparison With Previous Studies
Several previous studies have sought to document favorable changes in calcium regulation, manifest after repeated brief ischemia or during a later test occlusion, in preconditioned hearts versus controls.28 29 30 31 32 33 In contrast, our specific objective in protocol 2 was to focus on the possible role of brief transient calcium influx via Na+-H+ exchange during the preconditioning stimulus on subsequent infarct size reduction. Our results differ from the one previous study that also endeavored to measure infarct size with administration of a Na+-H+ exchange inhibitor in the setting of brief preconditioning ischemia. In contrast to our observations, Bugge and Ytrehus33 found that ethyl isopropyl amiloride, preconditioning, and the combination of preconditioning plus the amiloride analogue were equally protective in an isolated rat heart model of regional ischemia. Moreover, when the duration of sustained occlusion was prolonged such that the benefits of preconditioning began to wane, concomitant treatment with ethyl isopropyl amiloride augmented (rather than blocked) the reduction in infarct size achieved with preconditioning.33

How can these divergent results be reconciled? Although possible differences in the amiloride analogues used (dimethyl versus ethyl isopropyl amiloride),16 differences between the in vivo and isolated buffer-perfused heart models,11 and/or differences in calcium handling among species34 35 may play a role, a more plausible explanation may lie in the timing of treatment. As discussed previously, we administered intramyocardial injections of DMA 40 minutes before the onset of the test occlusion in an effort to facilitate diffusion and dissipation of the DMA and thereby preclude the well-documented cardioprotection observed when amiloride or its analogues are present during a sustained ischemic insult.22 23 24 25 26 In contrast, in the study by Bugge and Ytrehus, ethyl isopropyl amiloride was added to the perfusate before and throughout the preconditioning stimulus and maintained for 5 minutes into the period of sustained regional ischemia.33 These data suggest an intriguing paradox: prolonged infusion of the amiloride analogue may have abrogated the benefits of preconditioning yet protected the hearts by inhibition of Na+-H+ exchange during sustained occlusion. The concept that an agent or mediator (in this case amiloride) may both initiate protection (when present during sustained occlusion) and have deleterious effects (if administered during the preconditioning stimulus) is not without precedent. For example, a brief increase in intracellular calcium concentration in neurons has been reported to result in a sustained and favorable increase in the excitability of postsynaptic cells,14 36 and formation of oxygen radicals, generally thought to be a deleterious process, has been shown to protect the porcine heart against postischemic dysfunction caused by a brief ischemic insult occurring 1 day later.37 This explanation is speculative, however, and definitive resolution of our findings with those of Bugge and Ytrehus33 awaits further prospective study.

Limitations and Unanswered Questions
Our results imply that brief exposure of myocytes to increased calcium concentrations protects the canine heart against a subsequent 1-hour sustained period of coronary artery occlusion. Direct measurement of intracellular calcium levels during CaCl2 infusion and during brief preconditioning ischemia/reperfusion would clearly strengthen this hypothesis but is beyond the scope of our in vivo model. The results obtained with DMA treatment further imply that in the setting of brief preconditioning ischemia, influx of calcium occurs in large part via Na+-H+ exchange. As with all other studies performed with these agents in intact heart models, this conclusion is potentially confounded by the fact that even "selective" analogues of amiloride, including DMA, can also act on other ion transport systems, protein kinases, and enzymes.16 Importantly, however, the concentrations of DMA required to inhibit the Na+ channel, Na+-Ca2+ exchange, kinase activity, etc, are 10- to 1000-fold higher than the 400 µmol/L DMA briefly present (before diffusion) at the focal intramyocardial injection sites.

Although the results from both protocols 1 and 2 are consistent with the concept that calcium plays a role in initiating cardioprotection, the present study (1) does not conclusively prove that the cellular mechanisms responsible for infarct size reduction with CaCl2 infusion are the same as those for infarct size reduction with ischemic preconditioning; (2) does not address the possible relationship between calcium and other known or suspected mediators of preconditioning; and (3) was not designed to identify the second messengers, cellular pathways, or end effectors involved in the ultimate limitation of infarct size with either brief calcium infusion or brief preconditioning ischemia. Although these important ancillary questions remain to be answered, our results nonetheless implicate calcium as an important mediator of infarct size reduction achieved with preconditioning in the canine model.


*    Selected Abbreviations and Acronyms
 
AN = area of necrosis
AR = area at risk of infarction
CBF = coronary blood flow
DMA = 5-(N,N-dimethyl)-amiloride
IC = intracoronary
LAD = left anterior descending coronary artery
LV = left ventricular
PKC = protein kinase C
RMBF = regional myocardial blood flow
VF = ventricular fibrillation


*    Footnotes
 
Presented in part at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Fla, March 24-27, 1996, and the 69th Scientific Sessions of the American Heart Association, New Orleans, La, November 11-14, 1996, and published in abstract form (J Am Coll Cardiol. 1996;27[suppl A]:292A and Circulation. 1996;94[suppl I]:I-424).

Received November 5, 1996; revision received February 12, 1997; accepted February 20, 1997.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T. Infarct size–limiting effect of ischemic preconditioning is blunted by inhibition of 5'-nucleotidase activity and attenuation of adenosine release. Circulation. 1994;89:1237-1246.[Abstract/Free Full Text]

2. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994;266:H1145-H1152.[Abstract/Free Full Text]

3. Liu Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol. 1994;26:661-668.[Medline] [Order article via Infotrieve]

4. Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. Circulation. 1996;93:781-791.[Abstract/Free Full Text]

5. Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation. 1995;92:1546-1557.[Abstract/Free Full Text]

6. Simkhovich BZ, Przyklenk K, Hale SL, Patterson M, Kloner RA. Direct evidence that ischemic preconditioning does not cause protein kinase C translocation in rabbit heart. Cardiovasc Res. 1996;32:1064-1070.[Abstract/Free Full Text]

7. Vogt AM, Htun P, Arras M, Podzuweit T, Schaper W. Intramyocardial infusion of tool drugs for the study of molecular mechanisms in ischemic preconditioning. Basic Res Cardiol. 1996;91:389-400.[Medline] [Order article via Infotrieve]

8. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Reduction of infarct size with ischemic preconditioning and monophosphoryl lipid A: role of adenosine regulating enzymes? Am J Physiol. 1996;271:H1004-H1014.[Abstract/Free Full Text]

9. Kusuoka H, Koretsune Y, Chacko VP, Weisfeldt ML, Marban E. Excitation-contraction coupling in postischemic myocardium: does failure of activator Ca2+ transients underlie stunning? Circ Res. 1990;66:1268-1276.[Abstract/Free Full Text]

10. Amende I, Bentivegna LA, Zeind AJ, Wenzlaff P, Grossman W, Morgan JP. Intracellular calcium and ventricular function: effects of nisoldipine on global ischemia in the isovolumic, coronary-perfused heart. J Clin Invest. 1992;89:2060-2065.

11. Hata K, Takasago T, Saeki A, Nishioka T, Goto Y. Stunned myocardium after rapid correction of acidosis: increased oxygen cost of contractility and the role of the Na+-H+ exchange system. Circ Res. 1994;74:794-805.[Abstract/Free Full Text]

12. Opie LH. Role of calcium and other ions in reperfusion injury. Cardiovasc Drugs Ther. 1991;5:237-248.

13. Steenbergen C, Fralix TA, Murphy E. Role of increased cytosolic free calcium concentration in myocardial ischemic injury. Basic Res Cardiol. 1993;88:456-470.[Medline] [Order article via Infotrieve]

14. Marban E. Pathogenic role for calcium in stunning? Cardiovasc Drugs Ther. 1991;5:891-894.[Medline] [Order article via Infotrieve]

15. Pierce GN, Czubryt MP. The contribution of ionic imbalance to ischemia/reperfusion-induced injury. J Mol Cell Cardiol. 1995;27:53-63.[Medline] [Order article via Infotrieve]

16. Kleyman TR, Cragoe EJ. Amiloride and its analogs as tools in the study of ion transport. J Membr Biol. 1988;105:1-21.[Medline] [Order article via Infotrieve]

17. Ito BR, Tate H, Kobayashi M, Schaper W. Reversibly injured, postischemic canine myocardium retains normal contractile reserve. Circ Res. 1987;61:834-846.[Abstract/Free Full Text]

18. Whittaker P, Kloner RA, Przyklenk K. Intramyocardial injections and protection against myocardial ischemia: an attempt to examine the cardioprotective actions of adenosine. Circulation. 1996;93:2043-2051.[Abstract/Free Full Text]

19. Node K, Suzuki S, Tamai N, Hori M. Transient exposure to Ca2+ mediates the infarct-size limiting effect in the canine heart. Circulation. 1994;90(suppl I):I-209. Abstract.

20. Node K, Kitakaze M, Komamura K, Minamino T, Tada M, Inoue M, Hori M, Kamada T. Role of elevation of cellular Ca2+ in activation of ecto-5'-nucleotidase in ischaemic preconditioning. Eur Heart J. 1995;16:26. Abstract.[Medline] [Order article via Infotrieve]

21. Meldrum DR, Cleveland JC Jr, Sheridan BC, Rowland RT, Banerjee A, Harken AH. Cardiac preconditioning with calcium: clinically accessible myocardial protection. J Thorac Cardiovasc Surg. 1996;112:778-786.[Abstract/Free Full Text]

22. Meng HP, Pierce GN. Protective effects of 5-(N,N-dimethyl)amiloride on ischemia-reperfusion injury in hearts. Am J Physiol. 1990;258:H1615-H1619.[Abstract/Free Full Text]

23. Smart SC, LoCurto A, Schultz JE, Sagar KB, Warltier DC. Intracoronary amiloride prevents contractile dysfunction of postischemic `stunned' myocardium: role of hemodynamic alterations and inhibition of Na+-H+ exchange and L-type Ca2+ channels. J Am Coll Cardiol. 1995;26:1365-1373.[Abstract]

24. Myers ML, Mathur S, Li GH, Karmazyn M. Sodium-hydrogen exchange inhibitors improve postischaemic recovery of function in the perfused rabbit heart. Cardiovasc Res. 1995;29:209-214.[Medline] [Order article via Infotrieve]

25. Klein HH, Pich S, Bohle RM, Wollenweber J, Nebendahl K. Myocardial protection by Na+-H+ exchange inhibition in ischemic, reperfused porcine hearts. Circulation. 1995;92:912-917.[Abstract/Free Full Text]

26. Rohmann S, Weygandt H, Minck KO. Preischaemic as well as postischaemic application of a Na+-H+ exchange inhibitor reduces infarct size in pigs. Cardiovasc Res. 1995;30:945-951.[Medline] [Order article via Infotrieve]

27. Yao Z, Gross GJ. A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Circulation. 1994;89:1229-1236.[Abstract/Free Full Text]

28. Zucchi R, Ronca-Testoni S, Yu G, Galbani P, Ronca G, Mariani M. Effect of ischemia and reperfusion on cardiac ryanodine receptors: sarcoplasmic reticulum Ca2+ channels. Circ Res. 1994;74:271-280.[Abstract/Free Full Text]

29. Zucchi R, Ronca-Testoni S, Yu G, Galbani P, Ronca G, Mariani M. Postischemic changes in cardiac sarcoplasmic reticulum Ca2+ channels: a possible mechanism of ischemic preconditioning. Circ Res. 1995;76:1049-1056.[Abstract/Free Full Text]

30. Stokke M, Asknes G, Lande K, Hagelin EM, Bros O. Density of L-type calcium channels in ischaemically preconditioned porcine heart regions. Acta Physiol Scand. 1994;150:425-430.[Medline] [Order article via Infotrieve]

31. Smith GB, Stefenelli T, Wu ST, Wikman-Coffelt J, Parmley WW, Zaugg CP. Rapid adaptation of myocardial calcium homeostasis to short episodes of ischemia in isolated rat hearts. Am Heart J. 1996;131:1106-1112.[Medline] [Order article via Infotrieve]

32. Ramasamy R, Liu H, Anderson S, Lundmark J, Schaefer S. Ischemic preconditioning stimulates sodium and proton transport in isolated rat hearts. J Clin Invest. 1995;96:1464-1472.

33. Bugge E, Ytrehus K. Inhibition of sodium-hydrogen exchange reduces infarct size in the isolated rat heart: a protective additive to ischaemic preconditioning. Cardiovasc Res. 1995;29:269-274.[Medline] [Order article via Infotrieve]

34. Opie LH. Postischemic stunning: the case for calcium as the ultimate culprit. Cardiovasc Drugs Ther. 1991;5:895-900.[Medline] [Order article via Infotrieve]

35. Sham JSK, Hatem SN, Morad M. Species differences in the activity of the Na+-Ca2+ exchanger in mammalian cardiac myocytes. J Physiol. 1995;488:623-631.[Abstract/Free Full Text]

36. Regehr WG, Connor JA, Tank DW. Optimal imaging of calcium concentration in hippocampal pyramidal cells during synaptic activation. Nature. 1989;341:533-536.[Medline] [Order article via Infotrieve]

37. Sun SZ, Tang XL, Park SW, Qiu Y, Turrens JF, Bolli R. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest. 1996;97:562-576.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Br J AnaesthHome page
R. A. Bouwman, R. J. P. Musters, B. J. van Beek-Harmsen, J. J. de Lange, R. R. Lamberts, S. A. Loer, and C. Boer
Sevoflurane-induced cardioprotection depends on PKC-{alpha} activation via production of reactive oxygen species
Br. J. Anaesth., November 1, 2007; 99(5): 639 - 645.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Przyklenk, M. Maynard, C. E. Darling, and P. Whittaker
Pretreatment with D-myo-Inositol Trisphosphate Reduces Infarct Size in Rabbit Hearts: Role of Inositol Trisphosphate Receptors and Gap Junctions in Triggering Protection
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1386 - 1392.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Barrere-Lemaire, N. Combes, C. Sportouch-Dukhan, S. Richard, J. Nargeot, and C. Piot
Morphine mimics the antiapoptotic effect of preconditioning via an Ins(1,4,5)P3 signaling pathway in rat ventricular myocytes
Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H83 - H88.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. M. YELLON and J. M. DOWNEY
Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology
Physiol Rev, October 1, 2003; 83(4): 1113 - 1151.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Hattori, H. Otani, T. Uchiyama, H. Imamura, J. Cui, N. Maulik, G. A. Cordis, L. Zhu, and D. K. Das
Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning
Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1066 - H1074.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
A. Efstathiou, S. Seraskeris, C. Papakonstantinou, A. Aidonopoulos, and A. Lazou
Differential effect of preconditioning on post-ischaemic myocardial performance in the absence of substantial infarction and in extensively infarcted rat hearts
Eur. J. Cardiothorac. Surg., April 1, 2001; 19(4): 493 - 499.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Xu, Y. Wang, K. Hirai, A. Ayub, and M. Ashraf
Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis
Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H899 - H908.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Wang, J. Cone, and Y. Liu
Dual roles of mitochondrial KATP channels in diazoxide-mediated protection in isolated rabbit hearts
Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H246 - H255.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Avkiran
Protection of the Myocardium During Ischemia and Reperfusion : Na+/H+ Exchange Inhibition Versus Ischemic Preconditioning
Circulation, December 21, 1999; 100(25): 2469 - 2472.
[Full Text] [PDF]


Home page
CirculationHome page
R. J. Gumina, E. Buerger, C. Eickmeier, J. Moore, J. Daemmgen, and G. J. Gross
Inhibition of the Na+/H+ Exchanger Confers Greater Cardioprotection Against 90 Minutes of Myocardial Ischemia Than Ischemic Preconditioning in Dogs
Circulation, December 21, 1999; 100(25): 2519 - 2526.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Gysembergh, S. Lemaire, C. Piot, C. Sportouch, S. Richard, R. A. Kloner, and K. Przyklenk
Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart
Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2458 - H2469.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Karmazyn, X. T. Gan, R. A Humphreys, H. Yoshida, and K. Kusumoto
The Myocardial Na+-H+ Exchange : Structure, Regulation, and Its Role in Heart Disease
Circ. Res., October 29, 1999; 85(9): 777 - 786.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Wang and M. Ashraf
Role of Protein Kinase C in Mitochondrial KATP Channel–Mediated Protection Against Ca2+ Overload Injury in Rat Myocardium
Circ. Res., May 28, 1999; 84(10): 1156 - 1165.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Jovanovic, S. Jovanovic, E. Lorenz, and A. Terzic
Recombinant Cardiac ATP-Sensitive K+ Channel Subunits Confer Resistance To Chemical Hypoxia-Reoxygenation Injury
Circulation, October 13, 1998; 98(15): 1548 - 1555.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. A. Kloner, R. Bolli, E. Marban, L. Reinlib, and E. Braunwald
Medical and Cellular Implications of Stunning, Hibernation, and Preconditioning : An NHLBI Workshop
Circulation, May 19, 1998; 97(18): 1848 - 1867.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Chen, A. K. S. Camara, J. An, M. L. Riess, E. Novalija, and D. F. Stowe
Cardiac preconditioning with 4-h, 17{degrees}C ischemia reduces [Ca2+]i load and damage in part via KATP channel opening
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H1961 - H1969.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Kloner, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Kloner, R. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM CHLORIDE
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Medline Plus Health Information
*Heart Attack